BioLineRx Files 6-K, Incorporates Press Release into Registrations
Ticker: BLRX · Form: 6-K · Filed: Feb 28, 2024 · CIK: 1498403
Sentiment: neutral
Topics: regulatory-filing, press-release, corporate-update
TL;DR
**BioLineRx just filed a 6-K with a new press release, so keep an eye out for what they announced!**
AI Summary
BioLineRx Ltd. filed a 6-K report on February 28, 2024, indicating the issuance of a press release on the same date. This press release, filed as Exhibit 1, has its first paragraph incorporated by reference into all effective registration statements. The company, a foreign private issuer, maintains its principal executive offices at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Why It Matters
This filing signals that BioLineRx has new information to share with investors, potentially impacting its stock performance and future outlook.
Risk Assessment
Risk Level: low — This 6-K filing is a routine disclosure of a press release and does not inherently indicate a high-risk event.
Key Players & Entities
- BioLineRx Ltd. (company) — registrant
- February 28, 2024 (date) — date of filing and press release
- 001-35223 (other) — Commission file number
- 2 HaMa'ayan Street Modi'in 7177871, Israel (other) — Address of Principal Executive Offices
FAQ
What is the purpose of this 6-K filing by BioLineRx Ltd.?
The 6-K filing by BioLineRx Ltd. on February 28, 2024, is to report the issuance of a press release on the same date, which is filed as Exhibit 1 to the report.
When was this 6-K report filed?
This 6-K report was filed on February 28, 2024, and the Conformed Period of Report is also February 28, 2024.
What is the Commission file number for BioLineRx Ltd.?
The Commission file number for BioLineRx Ltd. is 001-35223.
Where are BioLineRx Ltd.'s principal executive offices located?
BioLineRx Ltd.'s principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
What is the significance of the press release mentioned in the filing?
The first paragraph of the press release attached to this Form 6-K is incorporated by reference into all effective registration statements filed by the registrant, indicating its importance to previously filed documents.
Filing Stats: 182 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-02-28 07:08:12
Filing Documents
- zk2431057.htm (6-K) — 9KB
- exhibit_1.htm (EX-99) — 19KB
- image00002.jpg (GRAPHIC) — 99KB
- 0001178913-24-000739.txt ( ) — 165KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On February 28, 2024, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. The first paragraph of the press release attached to this Form 6-K is hereby incorporated by reference into all effective registration Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: February 28, 2024